
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
